Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB cut its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 66.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,000 shares of the biopharmaceutical company’s stock after selling 33,350 shares during the quarter. Rhenman & Partners Asset Management AB’s holdings in Alnylam Pharmaceuticals were worth $4,000,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the company. Quantbot Technologies LP raised its stake in shares of Alnylam Pharmaceuticals by 1,754.5% in the third quarter. Quantbot Technologies LP now owns 204 shares of the biopharmaceutical company’s stock worth $56,000 after purchasing an additional 193 shares during the last quarter. Captrust Financial Advisors increased its holdings in Alnylam Pharmaceuticals by 34.4% in the 3rd quarter. Captrust Financial Advisors now owns 4,833 shares of the biopharmaceutical company’s stock worth $1,329,000 after buying an additional 1,237 shares during the period. Quantinno Capital Management LP raised its position in Alnylam Pharmaceuticals by 50.3% during the 3rd quarter. Quantinno Capital Management LP now owns 3,366 shares of the biopharmaceutical company’s stock worth $926,000 after buying an additional 1,126 shares during the last quarter. Kovitz Investment Group Partners LLC acquired a new stake in Alnylam Pharmaceuticals during the 3rd quarter valued at approximately $669,000. Finally, EP Wealth Advisors LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $201,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $235.74 on Friday. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The company has a 50-day moving average price of $259.03 and a 200 day moving average price of $260.33. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39. The stock has a market cap of $30.67 billion, a P/E ratio of -108.64 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 1,213 shares of the business’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $309,521.21. Following the sale, the chief executive officer now directly owns 81,526 shares in the company, valued at $20,802,989.42. This represents a 1.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total transaction of $362,246.40. Following the completion of the transaction, the executive vice president now directly owns 12,881 shares of the company’s stock, valued at approximately $3,240,344.36. The trade was a 10.06 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 71,234 shares of company stock valued at $19,958,097 over the last 90 days. 1.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

ALNY has been the topic of several recent research reports. Wells Fargo & Company upped their price target on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an “equal weight” rating in a report on Friday, March 21st. Citigroup raised their target price on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a “buy” rating in a report on Friday, March 21st. StockNews.com cut Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, March 21st. JPMorgan Chase & Co. raised shares of Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $280.00 to $328.00 in a research note on Monday, March 24th. Finally, Sanford C. Bernstein dropped their price target on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $316.25.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.